Penglie Zhang

2.0k total citations
37 papers, 1.2k citations indexed

About

Penglie Zhang is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Penglie Zhang has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Immunology and 13 papers in Hematology. Recurrent topics in Penglie Zhang's work include Chemokine receptors and signaling (13 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Receptor Mechanisms and Signaling (5 papers). Penglie Zhang is often cited by papers focused on Chemokine receptors and signaling (13 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Receptor Mechanisms and Signaling (5 papers). Penglie Zhang collaborates with scholars based in United States, Australia and United Kingdom. Penglie Zhang's co-authors include Thomas J. Schall, Juan C. Jaén, Jay P. Powers, Zhenhua Miao, Yu Wang, Brian A. Zabel, Bin Zhao, Anna Janowska‐Wieczorek, Ali Jalili and Susanna Lewén and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Penglie Zhang

36 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Penglie Zhang United States	18	586	583	350	155	108	37	1.2k
Karl Welzenbach Switzerland	15	636 1.1×	207 0.4×	586 1.7×	72 0.5×	103 1.0×	18	1.7k
Anna Garuti Italy	21	297 0.5×	477 0.8×	644 1.8×	205 1.3×	35 0.3×	67	1.5k
David V. Erbe United States	15	430 0.7×	240 0.4×	674 1.9×	74 0.5×	52 0.5×	25	1.3k
Anthony Neuger United States	15	502 0.9×	541 0.9×	635 1.8×	81 0.5×	93 0.9×	29	1.4k
Ben‐Quan Shen United States	19	292 0.5×	939 1.6×	797 2.3×	60 0.4×	41 0.4×	35	1.8k
Christine Bezombes France	24	662 1.1×	695 1.2×	1.2k 3.4×	106 0.7×	57 0.5×	55	2.2k
Jon Rosen United States	18	310 0.5×	462 0.8×	460 1.3×	444 2.9×	98 0.9×	24	1.6k
Toshihiro Mochizuki Japan	17	263 0.4×	302 0.5×	780 2.2×	155 1.0×	54 0.5×	27	1.3k
Susana Constantino Rosa Santos Portugal	17	224 0.4×	464 0.8×	664 1.9×	173 1.1×	22 0.2×	41	1.3k
J. Paul Secrist United States	18	469 0.8×	525 0.9×	1.6k 4.5×	123 0.8×	161 1.5×	25	2.0k

Countries citing papers authored by Penglie Zhang

Since Specialization

Citations

This map shows the geographic impact of Penglie Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penglie Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penglie Zhang more than expected).

Fields of papers citing papers by Penglie Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penglie Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penglie Zhang. The network helps show where Penglie Zhang may publish in the future.

Co-authorship network of co-authors of Penglie Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Penglie Zhang. A scholar is included among the top collaborators of Penglie Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penglie Zhang. Penglie Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gustavsson, Martin, S.A. Eberle, Pawel K. Dominik, et al.. (2022). Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias. Science Advances. 8(28). eabn8063–eabn8063. 43 indexed citations

Sullivan, Kathleen M., Linda Ertl, Zhenhua Miao, et al.. (2022). 499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model. Regular and Young Investigator Award Abstracts. A520–A520. 1 indexed citations

Zhao, Bin, James J. Campbell, Catherina L. Salanga, et al.. (2019). CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood. The Journal of Immunology. 203(12). 3157–3165. 19 indexed citations

Miao, Zhenhua, Linda Ertl, Dale Newland, et al.. (2018). CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS). PLoS ONE. 13(3). e0192405–e0192405. 8 indexed citations

Gustavsson, Martin, Liwen Wang, Noortje van Gils, et al.. (2017). Structural basis of ligand interaction with atypical chemokine receptor 3. Nature Communications. 8(1). 14135–14135. 79 indexed citations

Bekker, Pirow, Daniel J. Dairaghi, Lisa Seitz, et al.. (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS ONE. 11(10). e0164646–e0164646. 115 indexed citations

Duliège, Anne‐Marie, Stefan Sleijfer, A. Bischof, et al.. (2015). Abstract CT223: CCX872: Pharmacodynamic study of a potent and selective CCR2 antagonist in human volunteers and plans for phase Ib trial in patients with pancreatic cancer. Cancer Research. 75(15_Supplement). CT223–CT223. 2 indexed citations

Abe, Philipp, Dagmar Schütz, Fabienne Mackay, et al.. (2014). CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons. Development. 141(9). 1857–1863. 71 indexed citations

Walters, Matthew J., Karen Ebsworth, Timothy J. Sullivan, et al.. (2013). CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. Immunology Letters. 151(1-2). 44–47. 5 indexed citations

10.

Ebsworth, Karen, Matthew J. Walters, Linda Ertl, et al.. (2012). The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of glioblastoma.. Journal of Clinical Oncology. 30(15_suppl). e13580–e13580. 1 indexed citations

11.

Jia, Zhaozhong J., Robert M. Scarborough, Penglie Zhang, et al.. (2009). Design, Synthesis and Discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as Highly Potent Factor Xa Inhibitors. Chemical and Pharmaceutical Bulletin. 57(9). 1004–1007. 2 indexed citations

12.

Zabel, Brian A., Yu Wang, Susanna Lewén, et al.. (2009). Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands. The Journal of Immunology. 183(5). 3204–3211. 245 indexed citations

13.

Zhang, Penglie, Liang Bao, Zhaozhong J. Jia, et al.. (2009). Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR. Bioorganic & Medicinal Chemistry Letters. 19(8). 2186–2189. 10 indexed citations

14.

Zhu, Bing‐Yan, Zhaozhong J. Jia, Penglie Zhang, et al.. (2006). Inhibitory effect of carboxylic acid group on hERG binding. Bioorganic & Medicinal Chemistry Letters. 16(21). 5507–5512. 39 indexed citations

15.

Zhang, Penglie, Liang Bao, Zhaozhong J. Jia, et al.. (2004). Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity. Bioorganic & Medicinal Chemistry Letters. 14(4). 989–993. 19 indexed citations

16.

Jia, Zhaozhong J., Yanhong Wu, Wenrong Huang, et al.. (2004). 1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs. Bioorganic & Medicinal Chemistry Letters. 14(5). 1221–1227. 19 indexed citations

17.

Jia, Zhaozhong J., Ting Su, Yanhong Wu, et al.. (2004). N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(9). 2073–2078. 12 indexed citations

18.

Huang, Wenrong, Penglie Zhang, Lingyan Wang, et al.. (2003). Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(3). 561–566. 18 indexed citations

19.

Jia, Zhaozhong J., Yanhong Wu, Wenrong Huang, et al.. (2002). Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides. Bioorganic & Medicinal Chemistry Letters. 12(12). 1651–1655. 16 indexed citations

20.

Zhang, Penglie, John Woolfrey, Brian Huang, et al.. (2002). Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(12). 1657–1661. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact